Core Viewpoint - The company has disclosed its quarterly report, ensuring the accuracy and completeness of the financial information presented, and has not undergone an audit for this report [2][3][12]. Financial Data Summary - The company reported a fair value change gain of RMB 7.0927 million from its investment in WuXi Healthcare Ventures II, L.P. during Q1 2025 [5]. - The company completed a share buyback of 32,307,224 shares from March 10 to March 13, 2025, representing 1.42% of the total share capital, with a total expenditure of approximately RMB 79.99 million [8]. - The company has canceled and repurchased 1,653,000 restricted stocks from eight former employees who no longer meet the criteria for the 2024 restricted stock incentive plan [10]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders and the shareholding situation of the top ten shareholders were disclosed, with specific increases in holdings by certain private investment funds [6]. Important Events - The company held its first extraordinary general meeting of 2025 on February 6, 2025, resulting in an early board restructuring [7]. - The company’s potassium chloride oral solution received drug approval, enhancing its product offerings in the oral potassium supplement sector [11]. Legal Matters - The company is involved in a legal dispute with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) regarding an unpaid equity transfer payment of RMB 11.76 million, with the court ruling in favor of the company [9].